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Abstract
Background: Extracellular matrix metalloproteinase inducer (EMMPRIN; CD147, basigin) is an inducer of the
expression of several matrix metalloproteinases (MMPs). We reported previously that blocking EMMPRIN activity
reduced neuroinflammation and severity of disease in an animal model of multiple sclerosis (MS), experimental
autoimmune encephalomyelitis (EAE).
Methods: To improve upon EMMPRIN blockade, and to help unravel the biological functions of EMMPRIN in
inflammatory disorders, we have developed several anti-EMMPRIN monoclonal antibodies.
Results: Of these monoclonal antibodies, a particular one, clone 10, was efficient in binding mouse and human
cells using several methods of detection. The specificity of clone 10 was demonstrated by its lack of staining of
EMMPRIN-null embryos compared to heterozygous and wild-type mouse samples. Functionally, human T cells
activated with anti-CD3 and anti-CD28 elevated their expression of EMMPRIN and the treatment of these T cells
with clone 10 resulted in decreased proliferation and matrix metalloproteinase- 9 (MMP-9) production. Activated
human T cells were toxic to human neurons in culture and clone 10 pretreatment reduced T cell cytotoxicity
correspondent with decrease of granzyme B levels within T cells. In vivo, EAE mice treated with clone 10 had a
markedly reduced disease score compared to mice treated with IgM isotype control.
Conclusions: We have produced a novel anti-EMMPRIN monoclonal antibody that blocks several aspects of T cell
activity, thus highlighting the multiple roles of EMMPRIN in T cell biology. Moreover, clone 10 reduces EAE scores in
mice compared to controls, and has activity on human cells, potentially allowing for the testing of anti-EMMPRIN
treatment not only in EAE, but conceivably also in MS.
Keywords: Experimental autoimmune encephalomyelitis, Extracellular matrix metalloproteinase inducer, Function-
blocking antibody, Matrix metalloproteinases, Multiple sclerosis, Neuroinflammation T cell proliferation, Neurotoxicity
Background
Extracellular matrix metalloproteinase inducer (EMMPRIN;
basigin, CD147) is a member of the immunoglobulin (Ig)
superfamily. It is a cell surface glycoprotein expressed on
numerous cell types [1-4], with many binding partners in-
cluding CD98, monocarboxylate transporters (MCT-1),
cyclophilin, CD44, and hyaluronan to name but a few [5-7],
and a long list of acronyms including tumor collagenase
stimulatory factor (TCSF) [8]), M6 (in human cells) [3],
neurothelin, 5A11 and HT7 (chicken) [9-11], OX47 and
CE9 (rat) [1,12], and basigin and gp42 (human and mouse)
[2,13]. EMMPRIN was most recently shown to induce the
production of several matrix metalloproteinases (MMPs),
resulting in its renaming to EMMPRIN for ‘Extracellular
Matrix MetalloPRoteinase INducer’ [4,14].
EMMPRIN-null mice have abnormalities of body size,
memory function [15], female reproduction, spermatoge-
nesis [16,17], lung and liver tissue structure, blood–brain
barrier integrity [18], T cell cycling in the thymus [19] and
retinal function [20,21]. EMMPRIN-null mice are rarely
born due to prenatal loss around the time of implantation;
it is estimated that only about 30% of EMMPRIN-null
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embryos are born, of which 50% of surviving pups die of
interstitial pneumonia within the first week of life [16].
Thus, investigating the biology of EMMPRIN via these
constitutively null mice poses many challenges. We have
explored the roles of EMMPRIN by the generation and
use of anti-EMMPRIN function blocking antibodies in
this study.
Multiple sclerosis (MS) is an immune-mediated disease of
the central nervous system (CNS) with prominent demye-
lination and axonal degeneration. An animal model, experi-
mental autoimmune encephalomyelitis (EAE), mimics
several immunological and histological features of MS.
Many leukocyte subsets infiltrate into the CNS in MS and
EAE, and our group and others have previously reported on
several MMPs crucial in this infiltration process [22-24].
We recently found an important role for EMMPRIN as an
upstream regulator of the aberrant expression of MMPs in
EAE [25]. In that report, we described that a commercially
available function-blocking anti-mouse EMMPRIN anti-
body reduced MMP activity in the CNS resulting in
lowered EAE clinical severity and decreased leukocyte in-
filtration into the CNS [25].
Although a number of anti-EMMPRIN antibodies are
available commercially, these are generally used for par-
ticular applications and are species specific (Table 1). A
monoclonal anti-EMMPRIN with multiple applications
particularly function blocking activity, and capable of
recognizing both murine and human cells, would be ad-
vantageous as a therapeutic application in neuroinflam-
matory disorders. In the present study, we describe our
development of a novel anti-EMMPRIN function block-
ing monoclonal IgM antibody named clone 10 that
detects and affects EMMPRIN activity on both murine
and human cells. Our results suggest the potential use of
clone 10 as a therapeutic antibody in MS and other neu-
roinflammatory disorders.
Methods
Generation of a function blocking monoclonal
anti-EMMPRIN antibody
The extracellular domain 1 (EC1; Figure 1) of EMMPRIN
is responsible for the MMP induction function of
EMMPRIN [26]. We identified the amino acid sequence in
EC1 of murine and human EMMPRIN, determined
sequences within EC1 with the highest homology between
human and mouse EMMPRIN, and chose the peptide
spanning residues 40 to 55 of human EMMPRIN
(Figure 1) to be the immunogen. The University of Cal-
gary’s Peptide Services generated this peptide. Briefly,
BALB/C mice were subcutaneously immunized with the
EMMPRIN peptide emulsified in Freund’s complete adju-
vant. These mice were then boosted four times every
2 weeks with the EMMPRIN peptide emulsified in
Freund’s incomplete adjuvant. ELISA was used to deter-
mine the serum titers of antibodies. At 3 days after the
final booster injection, the mice were killed and spleens
were removed. Hybridomas were produced by the cell fu-
sion of Sp2/mIL6 mouse myeloid cells with spleen cells
from the immunized mice. Hybridomas were grown and
EMMPRIN-specific clones were selected by a positive reac-
tion of hybridoma supernatant to the EMMPRIN peptide
using ELISA, and verified using recombinant human EMM-
PRIN (R&D Systems, Minneapolis, MN, USA) and CNS tis-
sue in western blots. Selected hybridoma clones were then
inoculated into BALB/c mice by intraperitoneal injection.
At 18 days after inoculation, ascitic fluid samples were har-
vested from mice and then centrifuged at 1,000 g to remove
the solid fraction. IgM isotype of monoclonal antibodies
against EMMPRIN from ascites were purified by Protein A-
Sepharose CL-4B column chromatography.
Western blots
Recombinant human EMMPRIN (rhEMMPRIN; 5 μg/ml)
and mouse or human CNS tissues, sonicated in protein lysis
buffer containing 1% Triton X-100 and protease inhibitor
tablet (Roche Diagnostics, Mannheim, Germany), were
separated by SDS-PAGE on 12% gels, transferred to polyvi-
nylidene fluoride (PVDF) membranes, and probed using
hybridoma supernatants from clones. Secondary anti-
mouse antibodies conjugated with horseradish peroxidase
(HRP) were added and detected using an ECL chemilumi-
nesence kit (GE Lifesciences, Uppsala, Sweden). Mem-
branes were imaged using a gel documentation system
Table 1 Commercial antibodies to mouse or human extracellular matrix metalloproteinase inducer (EMMPRIN) utilized
in this study
Manufacturer (catalog no.) Clone, species Suggested use/dilution
e-Bioscience (12-1471) RL73.2, rat anti-mouse Fluorescence-activated cell sorting (1:50)
Serotec (MCA2283) OX-114, rat anti-mouse Immunofluorescence (1:500)
R&D Systems (MAB972) 116318, mouse anti-human Fluorescence-activated cell sorting (1:100)
US Biological (34-5600) E2260-03, rabbit anti-human Immunofluorescence (1:20-50)
Ancell (376-820) UM-8D6, mouse anti-human In vitro cell culture (10 μg/ml)
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(Syngene, Frederick, MD, USA). EMMPRIN appears
around 50 kDa in western blots [27].
PCR for genotyping
Ear punch samples from pups 3 to 4 weeks old were
digested in PBND digestion buffer (containing 50 mM
potassium chloride; 10 mM Tris–HCl, pH 8.3; 2.5 mM
magnesium chloride × 6 H20; 0.1 mg/ml gelatin; 0.45%
Nonidet P40; 0.45% Tween 20) with 20 μg/ml proteinase
K, and incubated at 55°C, shaking at 550 rpm, overnight.
Proteinase K was inactivated at 95°C for 10 minutes;
samples were spun down and 1 to 2 μl of sample was
used for PCR analysis. Using Taq polymerase and specific
primers for EMMPRIN wild-type (reverse sequence:
TGG CCT TCA CGC TCT TGA GC; forward: GCC
TCA TCT CTA AGA TCA CT) and null (Neo1 R
(neo1ATGATTGAACAAGATGGATTGCACG); Neo2 F
(neo2 TTCGTCCAGATCATCCTGATCGAC)) in the
presence of buffer, MgCl2, and deoxyribonucleotide tri-
phosphates (dNTPs), the PCR reaction was carried out
in a thermal cycler. Samples were run on a 2% agarose
gel containing SYBR Safe DNA gel stain (Invitrogen,
Carlsbad, CA, USA), and visualized using a Syngene Gel
documentation system (Syngene, Frederick, MD, USA).
Fluorescence-activated cell sorting (FACS)
Flow cytometry was performed using fluorescence-
conjugated antibodies against CD45-PercP (leukocytes; BD
Bioscience, Mississauga, Ontario, Canada), CD3-PE (T cells;
BD Bioscience), CD14-PE (monocytoid cells; BD Bio-
science), glial fibrillary acidic protein (GFAP)-fluorescein
isothiocyanate (FITC) (astrocytes; Sigma, Oakville,
Ontario, Canada), granzyme B-PE (T cell cytotoxicity; e-
Bioscience, San Diego, CA, USA) or EMMPRIN-PE
(CD147; e-Bioscience or R&D Systems). Briefly, cells
were suspended in FACS buffer (FB; phosphate-buffered
saline (PBS) + 2% fetal bovine serum), and blocked with
an Fc blocker CD16/CD32 (1:100; BD Bioscience) for 20
minutes at 4°C. Cells were washed in FB and incubated
in diluted antibodies of choice for 30 minutes at 4°C in
the dark. Cells were washed in FB and fixed in 1% for-
malin before being resuspended in FB and analyzed
using an LSRII FACS sorter.
EMMPRIN-null embryos
EMMPRIN heterozygous breeding pairs, a kind gift from
Dr Robert Senior (Washington University, St. Louis,
MO, USA), were set up and females were monitored for
plug formation to confirm mating. These heterozygote
mice were originally generated by Dr Muramatsu [16]
and given to Dr Senior for breeding and colony mainten-
ance. We obtained permission from Dr Muramatsu for
Dr Senior to transfer the mice to the University of
Calgary animal facility. Plugged females were separated
and 15 days later, these mice were humanely killed using
ketamine/xylazine anesthetic solution. E15 embryos were
individually dissected out and used in genotyping PCR,
immunofluorescence staining and FACS analysis.
Figure 1 Extracellular matrix metalloproteinase inducer (EMMPRIN) structure and peptide design. (A) The schematic structure of human
EMMPRIN shows that EMMPRIN consists of an extracellular domain, a transmembrane domain, a cytoplasmic domain and a signal peptide (based
on [26]). The two extracellular domains (EC) contain immunoglobulin-like (Ig-like) domains. The numbers represent the positions of amino acid
residues, and amino acids in circles in the two EC domains represent sites of glycosylation. (B) Amino acid sequence in murine EMMPRIN EC1
domain compared to human, with one peptide (40-55) selected based on the sequence responsible for the matrix metalloproteinase (MMP)
induction function of EMMPRIN, and the region that has the most homology between mouse and human EMMPRIN.
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Gelatin zymography
Gelatin gel zymography was used to identify MMP-2 and
MMP-9 present in mouse CNS tissue as previously
described [23]. Briefly, gelatin-binding proteins were first
enriched by treatment of samples with gelatin sepharose,
and they were then separated on a 10% polyacrylamide
gel containing 1 mg/ml gelatin under non-reducing con-
ditions. Gels were washed in a Triton X-100 renaturing
buffer, followed by incubation in developing buffer con-
taining 0.02% Brij 35, and then stained with Coomassie
blue followed by destaining.
Immunohistochemical and immunofluorescence staining
For immunofluorescence staining, CNS tissues from the
UK MS tissue bank, or mouse E15 embryo tissues were
sectioned using a cryostat (Lieca, Concord, Canada).
Each tissue section mounted on a glass slide was fixed in
-20°C methanol before blocking with 1% bovine serum
albumin (BSA) in PBS for 30 minutes. Clone 10 (10 μg/
ml), IgM isotype (10 μg/ml), or commercial anti-
EMMPRIN antibody (10 μg/ml; Serotec; US Biological,
Table 1) was applied to tissue sections and visualized
using Alexa 488-conjugated anti-mouse secondary anti-
body (Jackson Laboratories, West Grove, PA, USA). Sec-
tions were examined and photographed using an
Olympus BX51 fluorescence microscope and a Retiga
2000R camera (Q imaging, Surrey, BC, Canada). For
immunohistochemical staining, mouse EAE or control
spinal cords were snap frozen and sectioned using a
cryostat (Leica, Concord, Canada). Tissue sections were
mounted on a glass slide and dehydrated by dipping in
increasing concentration of ethanol for 1 minute each,
before being incubated in Luxol Fast Blue solution at 60°C
for 1 h. Slides were then rehydrated in 95% and 70%
ethanol before being dipped in 0.05% Lithium carbonate
for 10 to 15 s and washed in distilled water. All sections
were counterstained with hematoxylin and eosin and
coverslips were applied using mounting media (Acrytol).
Sections were viewed under an Olympus bright field
microscope (BH2) equipped with an Olympus Q Color 3
digital camera. Images were acquired using Imagepro
software (MediaCybernetics, Bethesda, MD, USA).
Isolation and treatment of human T cells
Human peripheral blood mononuclear cells (PBMCs)
were isolated from the blood of healthy adult volunteers
by Ficoll-Hypaque centrifugation (GE Healthcare Life
Sciences, Baie d’Urfe, Quebec, Canada) as previously
described [28,29]. The PBMCs were washed once with
phosphate-buffered saline (PBS) and suspended in
serum-free AIM-V medium (Invitrogen Life Technolo-
gies, Burlington, Ontario, Canada). To activate T cells in
the PBMC populations, 96-well round-bottomed plates
were coated with 100 ng/ml of purified mouse anti-
human CD3 (BD Pharmingen, Mississauga, Ontario,
Canada) for a period of 3 h. Then 10 ng/ml of anti-
CD28 (BD Pharmingen) was added as a suspension to
anti-CD3 wells for further activation, and human PBMCs
were plated at a density of 1 million cells/ml and cells
were left for 3 days at 37°C in a 5% humidified CO2 in-
cubator; we refer to the resultant anti-CD3/CD28
exposed cells as activated T cells. In some experiments,
IgM isotype control (10 μg/ml; BD Bioscience), or clone 10
(10 μg/ml), or anti-EMMPRIN (10 μg/ml; Ancell, Bayport,
MN, USA), or IgG isotype control (10 μg/ml; Ancell) were
added. Certain PBMC preparations did not receive anti-
CD3 or anti-CD28, and the floating cells collected 3 days
thereafter are referred to as non-activated T cells.
Carboxyfluorescein diacetate succinimidyl ester (CFSE)
labeling
PBMCs were prepared at a concentration of 20 × 106
cells/ml in incomplete RPMI media (containing 0.1%
fetal bovine serum (FBS)). CFSE stocks (5 mM in di-
methyl sulfoxide (DMSO); Molecular Probes, Eugene
OR, USA) were diluted 1:40 in incomplete RPMI media,
and 2 μl of this diluted CFSE solution was added per
0.1 ml of cells and mixed rapidly. After incubation at 37°C
for 10 minutes, the cell solution was diluted with 12 ml
of complete RPMI (containing 10% FBS) media, and
incubated at room temperature for 5 minutes to quench
the CFSE. The cells were then centrifuged twice and
washed in complete RPMI media. Cells were counted
and put into 96-well plates for treatment for 72 h. CFSE
incorporation into cells and its dilution in proliferating
cells was determined by FACS analysis.
Human T cell and neuron cocultures
Brain from human fetuses of 16 to 20 weeks fetal age
were obtained following therapeutic abortion according
to guidelines approved by local institutional ethics com-
mittees. Neuronal cultures in excess of 90% purity were
prepared as previously described [29,30]. Approximately
10 to 14 days after initial isolation, neurons were trypsi-
nized from T75 flasks, resuspended in minimal essential
medium (MEM) containing 10% fetal bovine serum, and
seeded at 100,000 cells/well onto 96-well flat-bottomed
plates precoated with polyornithine. Then, 2 days later,
the medium was switched to AIM V medium and
100,000 PBMCs activated the previous 48 h with 100 ng/
ml anti-CD3 and 10 ng/ml anti-CD28 were added to the
neurons. After 24 h of coculture the plates were washed
with PBS and fixed in 4% paraformaldehyde for 15 min-
utes, followed by incubation with mouse anti-
microtubule associated protein-2 (MAP-2) antibody and
secondary antibody to tag neurons. Hoechst dye was
then applied to label all nuclei.
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When clone 10 (10 μg/ml), or IgM isotype control
(10 μg/ml; BD Bioscience), or commercial anti-
EMMPRIN (10 μg/ml; Ancell, Table 1), or IgG isotype
control (10 μg/ml; Ancell) were used to determine
whether these alter T cell killing of neurons, they were
added to PBMCs 3 h after the initiation of anti-CD3/
CD28 exposure so that the initial activation of T cells
was unimpaired. Antibodies were not re-added during
the coculture of T cells and neurons so that their poten-
tial protective effect would be through activity of previ-
ously exposed T cells. To quantify the number of
neurons remaining in wells as a function of neurotox-
icity, images of MAP-2 and Hoechst-positive (4',6-diami-
dino-2-phenylindole (DAPI)) cells were captured using
ImageXpressMICRO (Molecular Devices, Sunnyvale, CA,
USA), then quantified by MetaXpressR Software (Mo-
lecular Devices) as per manufacturer instructions. Four
sites were analyzed per well.
Animals and EAE induction
Female C57BL/6 mice (Charles River, Wilmington, MA,
USA) 6 to 8 weeks old were utilized for EAE
immunization. All procedures are in accordance with
guidelines of the Canadian Council of Animal Care and
received approval from the local ethics committee. For
immunization, 50 μg of myelin oligodendrocyte glyco-
protein (MOG)35-55 peptide in complete Freund’s adju-
vant containing 10 mg/ml of heat inactivated
Mycobacterium tuberculosis H37RA (Difco, Lawrence,
KS, USA) was injected subcutaneously, 50 μl on either
side of the tail base. Animals were supplemented with
300 ng of pertussis toxin injected intraperitoneally on
days 0 and 2 after MOG immunization. The animals
were monitored daily for weight loss and changes of
EAE disease score using a scale of 1 to 15 described pre-
viously [31].
Clone 10 antibody administration to EAE mice
Clone 10 monoclonal antibody or rat IgM isotype control
(BD Bioscience) was injected intraperitoneally (50 μg/
mouse) in a volume of 100 μl into mice at days 8, 11 and 15
after MOG immunization.
Statistical analysis
All results are expressed as mean± SEM. The values
were assessed for statistical significance using the SPSS
V.19.0 software (SPSS, Chicago, IL, USA) to perform in-
dependent one-way analysis of variance (ANOVA) with
Tukey post hoc comparisons, and differences were con-
sidered significant at P <0.01. For EAE experiments we
performed a Mann–Whitney U non-parametric test and
differences were considered significant at P <0.05.
Results
Western blot analyses suggest that clone 10 detects
EMMPRIN in murine and human brain homogenates
In preliminary screenings, the conditioned media from
several hybridoma clones were found to be immunoreac-
tive to EMMPRIN peptide (40-55) (Figure 1) in ELISA
assays (data not shown). We focused on the 12 clones
(referred to as clones 1 to 13; no clone 5) with the
strongest immunoreactivity and proceeded to western
blots. We determined that clone 10 efficiently detected
rhEMMPRIN and a similar 55 kDa band in mouse brain
homogenates, while revealing a faint signal in human
brain homogenate at the same molecular weight
(Figure 2). The faint signal is likely due to a lower affinity
of clone 10 for human EMMPRIN at the level of western
blots, and/or to the low concentrations of anti-EMMPRIN
antibody titer in the test hybridroma supernatants.
Through isotyping analyses, clone 10 was found to be an
IgM with a kappa light chain.
Clone 10 efficiently and specifically binds EMMPRIN
Astrocytes in the CNS are known to express EMMPRIN
[25]. Thus, conditioned media from clones 1 to 13 (no
clone 5) were used in FACS analyses on astrocytes from
wild-type C57BL/6 mice. xWe found that the condi-
tioned medium from clone 10 stained mouse astrocytes
most efficiently compared to other clones, and that
its efficiency (Figure 3A) approached that of a commer-
cial anti-EMMPRIN antibody recommended for FACS
(e-Bioscience, Table 1).
E15 embryos from pregnant mice from heterozygous
mating were isolated and genotyped using PCR and FACS
(Figure 3B,C). Sections from genotype-verified embryos
were then stained with commercial anti-EMMPRIN anti-
body (Serotec, Table 1) and purified clone 10. Importantly,
no staining was detected in EMMPRIN-null tissue using
FACS or immunofluorescence with either antibody
(Figure 3C,D), demonstrating that clone 10 antibody is
specific for EMMPRIN.
Clone 10 efficiently binds to human cells in culture and
in vivo
We investigated whether clone 10 would bind to human
cells given our goal of generating an anti-EMMPRIN
antibody that could detect both mouse (Figure 3) and
human cells. Thus, conditioned media from clones 1 to
13 (no clone 5) were used to stain human astrocytes in a
FACS analysis (Figure 4A), and percentage of CD147+
(EMMPRIN) and GFAP+ cells were compared to a com-
mercial EMMPRIN antibody (R&D Systems, Table 1).
Clone 10 stained human astrocytes most efficiently com-
pared to the other clones, although clone 1 also stained
astrocytes quite efficiently.
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Next, we considered whether clone 10 could stain
human brain sections. Given our previous report [25] of
the upregulation of EMMPRIN in MS, we used tissue sec-
tions from MS specimens containing areas of perivascular
inflammation (Figure 4B). Figure 4B1 shows immunoflour-
escence staining of postmortem human MS CNS samples
with laminin and CD45 to illustrate a perivascular cuff
found prominently in active MS cases. Laminin demarcates
the basement membranes surrounding a post-capillary ven-
ule within the CNS and CD45 stains all infiltrating leuko-
cytes. The presence of many leukocytes trapped within the
laminin layers indicates a perivascular inflammatory cuff
with ongoing immune cell influx into the CNS (inset of
Figure 4B1). Staining for GFAP (glial fibrillary acidic pro-
tein; in green; Figure 4B, panels 3, 4, 6, 7, 9, 10) to detect
astrocytes, and with clone 10 (Figure 4B2) and commercial
anti-EMMPRIN (US biological, Table 1, Figure 4B8) shows
a comparable expression of EMMPRIN (red staining) on
astrocytes with both antibodies. Tissues stained with IgM
isotype control (Figure 4B5) had minimal signal, implying
staining specificity for EMMPRIN with clone 10.
Clone 10 reduces proliferation of human T cells
Non-cultured human T cells immediately post isolation
express very low levels of EMMPRIN (non-cult.;
Figure 5A,D). Non-activated human T cells that are cul-
tured for 72 h express higher levels of EMMPRIN in
comparison (non-act.; Figure 5B,D). Upon exposure to
anti-CD3 and anti-CD28 to activate T cells, EMMPRIN
expression increased in human PBMCs (act.; Figure 5C,
D). These trends in EMMPRIN levels were similar in T cells
from four individual volunteers (Figure 4D). To determine
the roles of EMMPRIN, clone 10 and a commercial anti-
body to human EMMPRIN (Ancell; Table 1) were applied
during the activation process with anti-CD3/CD28. The ex-
posure to anti-CD3/CD28 significantly increased the pro-
liferation of T cells as depicted by the increased
incorporation of 3[H] thymidine (***P <0.001; Figure 5E),
and the dilution of CFSE detected by FACS (act.;
Figure 5F,G). Treatment of activated T cells with clone
10 or commercial anti-EMMPRIN antibody (Ancell;
Table 1) significantly reduced T cell proliferation (***P
<0.001; Figure 5E-G). This reduction in proliferation is
EMMPRIN specific, as it was not observed when activated
T cells were treated with the same amount of IgM isotype
control (Figure 5E-G), or IgG isotype control (Figure 5E).
Furthermore, to examine a loss in the MMP-induction
function of EMMPRIN by treatment with clone 10, we
analyzed non-activated (non-act.) and activated (act.) T
cells for their levels of MMP-9 using gelatin zymography.
Conditioned media were examined since MMP-9 is a
secreted protease. Figure 5H shows that activated T cells
produce significant amounts of MMP-9 and this was
reduced in clone 10 treated cells versus those treated
with IgM isotype control (Figure 5H).
T cell-mediated neuron killing
Activated T cells are toxic to human neurons in culture
as previously described [29] (Figure 6). Using ImageX-
press analysis, we found a significantly reduced number
of microtubule-associated protein 2 (MAP2)-positive
neurons in wells cocultured with activated T cells (neu-
rons + act. T cells; ***P <0.001) but not in wells cocul-
tured with non-activated T cells (neurons + non-act. T
cells; Figure 6B,C). In the presence of clone 10, T cell
mediated toxicity to neurons was significantly reduced,
shown by more neurons in neuron-T cell cocultures
(Figure 6B,C; ***P <0.001), compared to T cells treated
Figure 2 Clone 10 binds most efficiently to extracellular matrix metalloproteinase inducer (EMMPRIN) in western blots. Hybridoma
supernatants from several clones are used in a western blot to detect 5 μg of recombinant human EMMPRIN (rhE; lane 1), 10 μg of mouse central
nervous system (CNS) homogenate (m; lane 2) and 10 μg of human CNS homogenate (h; lane 3), EMMPRIN has an approximate molecular weight
of 55 kDa.
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with IgM isotype control (Figure 6B). Furthermore,
granzyme-B levels, normally high in activated T cells and
implicated as mediators of cytotoxicity [32] were signifi-
cantly reduced in activated T cells treated with clone 10
compared to those treated with IgM isotype control
(Figure 6D; ***P <0.001).
Treatment with clone 10 reduces mouse EAE disease
severity
We have previously demonstrated that [25] treatment of
EAE mice around disease onset, with a commercially avail-
able anti-EMMPRIN antibody (e-Bioscience; Table 1),
reduces EAE severity in these mice, compared to mice
(See figure on previous page.)
Figure 3 Clone 10 specificity and binding efficiency in mouse tissue. Using fluorescence-activated cell sorting (FACS) analysis (A), mouse
astrocytes identified by glial fibrillary acidic protein (GFAP) were examined for extracellular matrix metalloproteinase inducer (EMMPRIN) expression
using hybridoma supernatants from several clones (1 to 13, no clone 5) and commercial anti-mouse EMMPRIN antibody (e-Bioscience). Tissues
from E15 embryos were used to determine genotype by PCR (B), where a band at 285 bp identified the PCR product for neo primers (knockout
(KO) band), and a band at 503 bp identified the PCR product for EMMPRIN wild-type (WT); these tissues were subjected to FACS analysis (C) for
EMMPRIN WT, heterozygous (Het) and KO mice. (D) EMMPRIN WT, Het and KO tissues were used in immunofluorescence staining with clone 10,
IgM isotype control or commercial anti-EMMPRIN antibody (Anti-EMMPRIN; Serotec). Importantly, clone 10 and the Serotec antibody did not stain
EMMPRIN KO tissue.
Figure 4 Clone 10 binding efficiency in human cells and tissue. (A) Using fluorescence-activated cell sorting (FACS) analysis, human fetal
astrocytes stained for glial fibrillary acidic protein (GFAP) were additionally stained with hybridoma supernatants from several clones (1 to 13, no
clone 5) and with the commercial anti-human extracellular matrix metalloproteinase inducer (EMMPRIN) antibody (R&D Systems).
(B) Immunofluorescence staining of postmortem multiple sclerosis (MS) brain samples for laminin/CD45 (1; higher magnification inset) and GFAP
(3, 4, 6, 7, 9, 10), and with clone 10 (2, 4), IgM isotype control (5, 7) and commercial anti-EMMPRIN (US Biological, Table 1) antibodies (8, 10).
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treated with an isotype control. In this study we wanted to
examine whether our monoclonal anti-EMMPRIN anti-
body (clone 10) is capable of functioning similarly to the
commercial anti-EMMPRIN antibody in vivo. We treated
one group of EAE mice with clone 10 and another group
with IgM isotype control on days 8, 11, and 15 post MOG
immunization, and monitored EAE disease scores daily.
EAE mice treated with clone 10 had significantly lower
disease scores overall (P=0.04; Mann–Whitney U test)
compared to mice treated with IgM isotype control
(Figure 7A). Histological analysis of longitudinal sections
of spinal cords using hematoxylin and eosin with Luxol
Fast Blue staining revealed spared myelin sheaths and the
presence of little to no inflammatory cells in EAE animals
treated with clone 10 compared to those treated with IgM
isotype control (Figure 7B). These results are documented
at both 10× and 20× original magnification to show differ-
ences between groups.
Discussion
In MS and EAE, leukocytes cross the blood–brain
barrier to enter the CNS parenchyma where they des-
troy myelin and the underlying axons [33]. Several
roles for MMPs are implied in the pathology of MS
and EAE [34-37], and many MMP members are ele-
vated in the serum, cerebrospinal fluid and brain tis-
sue of patients with MS (reviewed in [37]), and in the
CNS of mice afflicted with EAE [22,31]. Importantly,
MMPs are shown to be crucial in leukocyte trafficking
into the CNS [38,39], specifically in the cleavage of
components of the blood–brain barrier [23] that aids
their entry into the CNS parenchyma.
The use of MMP inhibitors (reviewed in [37]) or using
MMP-null mice [23,40-42] in EAE has proven to be
challenging as several MMPs are upregulated simultan-
eously, and blocking one or two of them may be insuffi-
cient as many MMP members compensate for each
other. To overcome this issue, we previously used a com-
mercially available mouse specific anti-EMMPRIN function-
blocking antibody (e-Bioscience) to treat EAE mice at various
timepoints [25]. This treatment not only resulted in a
marked decrease in MMP activity, but it reduced EAE
disease severity. The utility of this commercial e-Bioscience
antibody in EAE is not translatable to MS as the antibody
has poor efficacy on human cells (data not shown).
The MMP induction function of EMMPRIN has been
investigated quite thoroughly by several groups inter-
ested in tumor and cancer biology [4,8,43,44]. Specific-
ally, the peptide sequence of EMMPRIN that is
responsible for MMP induction has been identified
[45] to lie within the EC1 (amino acid residues 22 to
50) domain in both mouse and human EMMPRIN.
Interestingly, it is reported that the asparagine amino
acid within this specific peptide region of EMMPRIN
needs to be glycosylated for efficient MMP induction by
EMMPRIN [46]. Many monoclonal antibodies
for EMMPRIN have been reported to reduce MMP pro-
duction by EMMPRIN in tumor cells both in vitro and
in vivo [45,47-50], including the commercial anti-mouse
EMMPRIN (e-Bioscience) we reported in EAE recently
[25]. The biggest drawback of these antibodies is that they
do not crossreact between mouse and human EMMPRIN.
To investigate the potential of an anti-EMMPRIN anti-
body therapy in MS, it would be desirable to have an anti-
body that will affect murine as well as human cells, so that
preclinical work can be performed in mice prior to transla-
tion into humans. To develop an anti-EMMPRIN function-
blocking antibody that crossreacts with mouse and human
EMMPRIN, we chose a peptide spanning residues 40 to 55
of the MMP-inducing region of EC1 domain of EMMPRIN;
this region also contains the site of glycosylation indicated
to be important in efficient MMP induction by EMMPRIN
[51], and it has maximum homology between mouse and
human EMMPRIN (Figure 1).
In this study we describe a novel monoclonal function
blocking anti-EMMPRIN antibody (clone 10) that recog-
nizes both mouse and human targets in binding studies
(Figures 3 and 4). Clone 10 also recognized rhEMMPRIN
and a similar sized mass in mouse tissue in west-
ern blots (Figure 2), although it detected human tissue
only faintly. This may be due to differentially glycosy-
lated forms of EMMPRIN in human versus mouse sam-
ples that may mask EMMPRIN from clone 10 in human
homogenates (Figure 2). Critically, we determined that
(See figure on previous page.)
Figure 5 Clone 10 treatment reduces T cell proliferation and activation. Extracellular matrix metalloproteinase inducer (EMMPRIN) levels in
non-cultured T cells immediately upon isolation ((A); non-cult.), cultured without activation ((B); non-act.), and cultured for 72 h with anti-CD3 and
anti-CD28 ((C); act.) are compared using fluorescence-activated cell sorting (FACS) analysis. EMMPRIN levels in T cells from four individual
volunteers are displayed (D). Human PBMCs incubated in the absence (non-act.) or presence (act.) of anti-CD3 and anti-CD28 were treated with
various concentrations of clone 10, IgM isotype control, a commercial anti-human EMMPRIN antibody (Ancell) and IgG Isotype control. After 48 h
cells were incubated with tritiated thymidine and proliferation assessed (E); results are mean± SEM of quadruplicates; ***P <0.001 compared to
act. T cells (one-way analysis of variance (ANOVA) with Tukey’s post hoc comparisons). Similarly, non-activated and activated cells were treated
with clone 10 or IgM isotype control and carboxyfluorescein diacetate succinimidyl ester (CFSE) intensity was determined in CD3+ cells by FACS
analysis (F) and quantified (G). Gelatin zymography was used to determine matrix metalloproteinase 9 (MMP-9) levels in conditioned media from
peripheral blood mononuclear cells (PBMCs) non-activated (non-act.), activated (act.), activated and with clone 10 treatment (act. + C10), and
activated with IgM isotype treatment (act. + IgM) (H).
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clone 10 is specific for EMMPRIN by its staining of
embryos that are EMMPRIN wild-type or heterozygote,
but not in EMMPRIN-null embryos. Besides its capacity
to bind both human and mouse tissue in western blots,
clone 10 was useful in applications such as immuno-
fluorescence staining and FACS analysis. These charac-
teristics offer clone 10 as advantageous to other EMMPRIN
antibodies that often are species specific, or applicable to a
limited spectrum of uses. Moreover, clone 10 is a function-
blocking antibody that reduced the proliferation of T cells,
decreased the capability of T cells to secrete MMP-9 into
the culture medium, and attenuated the cytotoxicity of acti-
vated T cells on neurons. Taken together, this information
suggests clone 10 is a new and robust tool in understanding
EMMPRIN biology and will help to unravel its roles in neu-
roinflammation and MS.
Human T cells that are activated with anti-CD3 and
anti-CD28 proliferate and undergo cell cycling quite
Figure 6 Clone 10 treatment reduces T cell neurotoxicity. Peripheral blood mononuclear cells (PBMCs) incubated in the absence (non-act.) or
presence of anti-CD3 and anti-CD28 (act.) were applied to human fetal neurons, and neuronal killing was then assessed (A). Using ImageXpress
analysis, the number of microtubule-associated protein 2 (MAP2) + neurons in defined fields per well was enumerated; neuronal counts were
reduced by activated T cells, representing neuronal death, and this was prevented by clone 10 treatment of T cells (B). Values are mean± SEM of
quadruplicate wells; ***P <0.001 (one-way analysis of variance (ANOVA) with Tukey’s post hoc comparisons). (C) Representative images of MAP2-
labeled neurons. Fluorescence-activated cell sorting (FACS) analysis was used to estimate Granzyme B levels in CD3+ T cells with or without
treatment with clone 10 (D). Values in (D) are mean± SEM of triplicates samples; ***P <0.001 (one-way ANOVA with Tukey’s post hoc
comparisons).
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extensively. We find that treatment of activated T cells
with clone 10 reduces their proliferative and cell cycling
capacity (Figure 5). This finding is very interesting as it
suggests a role for EMMPRIN in the T cell activation
cascade, a function that may or may not be MMP
dependent. Indeed, the latter is suggested by our
finding that the proliferation of activated T cells is not
altered by a pan-MMP inhibitor, BB94, at a concentra-
tion (100 nM) that prevents manifestation of MMP ac-
tivity (data not shown). Thus, clone 10 may be a useful
antibody to explore functions of EMMPRIN other than
MMP induction.
Figure 7 Treatment with clone 10 attenuates experimental autoimmune encephalomyelitis (EAE) disease severity. (A) Mice immunized
for EAE were treated with 50 μg/mouse of clone 10 (red circles) or IgM isotype control (Black squares) at days 8, 11 and 15 (arrows) post-myelin
oligodendrocyte glycoprotein (MOG) immunization. EAE disease severity was found to be significantly reduced in clone 10 treated animals
compared with mice treated with an IgM isotype control. The data points have an overall statistical difference between timepoints 10 and 16
(*P= 0.04, Mann Whitney U test). Results are mean± SEM from five mice each; this trend was reproduced in another experiment. (B) Spinal cord
sections from EAE animals treated with clone 10 or IgM isotype control and killed at day 16 were stained with hematoxylin and eosin and Luxol
Fast Blue to determine sites of immune cell infiltration and myelin sheaths. Images were captured at 10 × and 20 × original magnification.
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Furthermore, it has been previously reported that acti-
vated T cells are cytotoxic [29,52] to human neurons
with a role for a specific population of human T cells
(CD4+CD25+CD127dimFoxp3+) [52] that use gran-
zyme B as a mechanism to destroy neurons [32]. We
show here that activated human T cells that are pre-
treated with clone 10 were less cytotoxic to human neu-
rons compared to activated T cells that were not
pretreated with any antibodies or those pretreated with
IgM isotype control (Figure 6). These findings suggest a
role for EMMPRIN in T cell cytotoxicity and provide fur-
ther evidence that clone 10 is an effective function-
blocking antibody. Specifically, our results suggest a role
for EMMPRIN in the granzyme B mediated cytotoxic
pathway of T cells.
Finally, to examine the therapeutic potential of clone
10 in MS, and to determine its effectiveness in vivo, we
injected clone 10 into EAE animals just prior to onset, at
onset and shortly after disease onset (Figure 7A). Com-
pared to EAE animals treated with IgM isotype control,
animals treated with clone 10 had lowered clinical dis-
ease scores (Figure 7A), and had more spared spinal cord
tissue, with intact myelin sheaths and reduced inflamma-
tion (Figure 7B). These results suggest that clone 10 can
potentially be used as an in vivo anti-EMMPRIN func-
tion-blocking antibody in future animal experiments
prior to considering humanizing it for use in MS thera-
peutic trials.
Conclusions
In this study we describe a novel monoclonal anti-
EMMPRIN function-blocking antibody that crossreacts with
mouse and human EMMPRIN, is specific for EMMPRIN,
that not only efficiently blocks the MMP induction function
of EMMPRIN, but also brings to light potential roles
of EMMPRIN in neuroinflammatory diseases such as MS.
Testing clone 10 in EAE demonstrated that blocking
EMMPRIN is beneficial and suggests that the use of clone
10 could be a potential therapy for MS.
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